Log in

Relevant bibliographies by topics / Organ transplantation; Immunosuppression

Contents

Journal articles
Dissertations / Theses
Books
Book chapters

Academic literature on the topic 'Organ transplantation; Immunosuppression'

Author: Grafiati

Published: 4 June 2021

Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Organ transplantation; Immunosuppression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Organ transplantation; Immunosuppression"

1

Oka, Takahiro. "Immunosuppression in Organ Transplantation." Japanese Journal of Pharmacology 64 (1994): 3. http://dx.doi.org/10.1016/s0021-5198(19)35809-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Oka, Takahiro, and Norio Yoshimura. "Immunosuppression in Organ Transplantation." Japanese Journal of Pharmacology 71, no. 2 (1996): 89–100. http://dx.doi.org/10.1254/jjp.71.89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Carpenter, Charles B. "Immunosuppression in Organ Transplantation." New England Journal of Medicine 322, no. 17 (April 26, 1990): 1224–26. http://dx.doi.org/10.1056/nejm199004263221709.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sonmez, Yusuf Ercin. "Future of Solid Organ Transplantation: Organ-Specific Tolerance." KIDNEYS 10, no. 3 (September 15, 2021): 130–36. http://dx.doi.org/10.22141/2307-1257.10.3.2021.239589.

Full text

Abstract:

A transplant between two people who are not genetically identical is called an allotransplant and the process is called allotransplantation. Donor organs and tissues can be from people who are living, or people who have died because of a significant brain injury or lack of circulation. Allotransplantation can create a rejection process where the immune system of the recipient attacks the foreign donor organ or tissue and destroys it. The recipient may need to take immunosuppressive medication for the rest of their life to reduce the risk of rejection of the donated organ. In general, deliberately induced immunosuppression is performed to prevent the body from rejecting an organ transplant. The adverse effects associated with these agents and the risks of long-term immunosuppression present a number of challenges for the clinician. Immune tolerance, or immunological tolerance, or immunotolerance, is a state of unresponsiveness of the immune system to substances or tissue that have the capacity to elicit an immune response in a given organism.

APA, Harvard, Vancouver, ISO, and other styles

5

Starzl, Thomas E., Noriko Murase, Kareem Abu-Elmagd, Edward A. Gray, Ron Shapiro, Bijan Eghtesad, Robert J. Corry, et al. "Tolerogenic immunosuppression for organ transplantation." Lancet 361, no. 9368 (May 2003): 1502–10. http://dx.doi.org/10.1016/s0140-6736(03)13175-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jasiak, Natalia M., and Jeong M. Park. "Immunosuppression in Solid-Organ Transplantation." Critical Care Nursing Quarterly 39, no. 3 (2016): 227–40. http://dx.doi.org/10.1097/cnq.0000000000000117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Eggleton, Alison. "Immunosuppression following solid organ transplantation." Nurse Prescribing 12, no. 6 (June 2, 2014): 274–75. http://dx.doi.org/10.12968/npre.2014.12.6.274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ohara, Margaret M. "Immunosuppression in solid organ transplantation." Topics in Clinical Nutrition 7, no. 3 (July 1992): 6–11. http://dx.doi.org/10.1097/00008486-199206000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Pezze, JL. "RATG: implications for nursing care in organ transplantation." Critical Care Nurse 10, no. 9 (October 1, 1990): 18–19. http://dx.doi.org/10.4037/ccn1990.10.9.18.

Full text

Abstract:

Proper immunosuppression is a key element determining the survival of patients undergoing organ transplantation. RATG is one of several immunosuppressive agents available for use. Nurses need to recognize the unique challenges that RATG poses for patient and dosage preparation, along with those affecting its administration and post administration. Doing so can effectively aid the transplanted patient in achieving optimal immunosuppression with the least amount of unpleasant effects. The hospital stay for a transplant patient can be very frustrating and exhausting. Nursing interventions that limit these effects can foster a more desirable patient experience.

APA, Harvard, Vancouver, ISO, and other styles

10

Cai, Songjie, and Anil Chandraker. "Cell Therapy in Solid Organ Transplantation." Current Gene Therapy 19, no. 2 (August 20, 2019): 71–80. http://dx.doi.org/10.2174/1566523219666190603103840.

Full text

Abstract:

Transplantation is the only cure for end-stage organ failure. Current immunosuppressive drugs have two major limitations: 1) non antigen specificity, which increases the risk of cancer and infection diseases, and 2) chronic toxicity. Cell therapy appears to be an innovative and promising strategy to minimize the use of immunosuppression in transplantation and to improve long-term graft survival. Preclinical studies have shown efficacy and safety of using various suppressor cells, such as regulatory T cells, regulatory B cells and tolerogenic dendritic cells. Recent clinical trials using cellbased therapies in solid organ transplantation also hold out the promise of improving efficacy. In this review, we will briefly go over the rejection process, current immunosuppressive drugs, and the potential therapeutic use of regulatory cells in transplantation.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Organ transplantation; Immunosuppression"

1

Ruers, Theodoor Jacques Marie. "Selective immunosuppression in organ transplantation." Maastricht : Maastricht : Rijksuniversiteit Limburg ; University Library, Maastricht University [Host], 1989. http://arno.unimaas.nl/show.cgi?fid=5415.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Koshiba, Takaaki. "Implication of immunosuppression in tolerance after organ transplantation." Kyoto University, 2003. http://hdl.handle.net/2433/148727.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gilot, Bryant Joseph. "Visualisation of cytotoxic T cells during allograft rejection and tolerance." Thesis, University of Oxford, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.326006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Jones, Nick D. "Tolerance induction by intrathymic injection of foreign alloantigen : examination of mechanisms using TCR transgenic mice." Thesis, University of Oxford, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.360362.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gieschen-Krische, Mary. "The role of NKT cells following solid organ transplantation." Thesis, University of Manchester, 2014. https://www.research.manchester.ac.uk/portal/en/theses/the-role-of-nkt-cells-following-solid-organ-transplantation(321a0a4b-336e-44dd-a608-58f7ea58e27e).html.

Full text

Abstract:

Introduction: NKT cells are categorised as borderline between NK and T cells, sharing phenotypic and functional characteristics of both cells, demonstrating their capacity to contritube to both pro- or anti-inflammatory processes. However, the role of these cells among lung transplant recipients remains largely unknown. The aim of this study was to determine the role of NKT cells following lung transplantation. Methods: NKT cells were quantified and characterised according to markers of: activation (CD107a, CD161, NKG2D) and immunomodulation (CD200 and CD200R) in peripheral blood and BALs. NKT cell numbers and phenotypes were correlated to clinical variables: immunosuppression, acute rejection, acute infections (viral, bacterial and fungal), bronchiolitis obliterans syndrome (BOS grade), lung function, and demographic variables. Interactions between NKT cells and the transplanted lung were linked by determining the relative expression of immunomodulatory ligand CD200 in lung biopsies. In vitro models were employed to determine the role of NKT cells to acute lung injury, either alone or in combination with cells of the mononuclear phagocyte system (MPS). Results: Higher numbers of immunomodulatory NKT cells (CD200+ and CD200R+) were found as lung function decreased. Data from peripheral blood indicates that recipients whose donors or themselves had been exposed to CMV infection demonstrated increased numbers of NKT cells. Patients with active EBV infections demonstrated higher NKT cell numbers expressing CD200 and CD200R. Data from BALs, indicates that patients with active fungal infections present higher immunomodulatory (CD200R) NKT cells and lower cytotoxicity marker (CD107a). In peripheral blood, lung recipients demonstrated higher NKT cell numbers compared to healthy volunteers. However, the lower relative mean expression of functional markers in the lung transplant group suggests that cells are less active. In vitro cultures with immunosuppressants demonstrated that cell cycle inhibitors (MMF and AZA) and corticosteroids (Prednisolone) are likely to inhibit NKT cell proliferation, while calcineurin inhibitors (Cyclosporine A and Tacrolimus) decrease the relative mean expression of activation markers. Clinical observations indicate that higher doses of Azathioprine may correlate with increased NKT cell numbers and the relative expression of CD200 and CD200R. However, under these conditions the relative expression of activation marker NKG2D decreases. In vitro data from the acute injury model indicates that NKT cells are capable to migrate into the injured lung and become activated following transmigration which is facilitated by the presence of monocytes. We also observed the interaction of NKT cells with endothelial cells, monocytes and macrophages. Also, the relative mean expression of CD200 and CD200R increased at the capillary layer, regardless of injury while upregulation of activation markers (CD107a, CD161 and NKG2D) was found at the capillary layer, following injury. In contrast, the alveolar layer demonstrated a decrease in both activation and immunomodulatory markers, following acute injury. Conclusions: Despite immunosuppression, NKT cells remain present in peripheral blood and BAL following lung transplantation. NKT cell proliferation is likely to be reduced by effect of cell cycle inhibitors, while calcineurin inhibitors exert an immunomodulatory effect. Our data indicates that NKT cells can participate in inflammatory and immunomodulatory events at the alveolar bilayer. Their capacity to infiltrate the lungs was assisted by cells of the mononuclear phagocyte system (MPS), which play an important role in antigen presentation and modulation of acute injury. Further research is needed to elucidate the signals and mechanisms occurring between NKT and MPS interactions and the outcomes these populations drive in acute lung injury.

APA, Harvard, Vancouver, ISO, and other styles

6

Mohamed, Mostafa A. S. "TGF-β expression in solid organ transplantation : a comparative study between cyclosporin A and Tacrolimus." Thesis, University of Newcastle Upon Tyne, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.314176.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wulff, Brian Charles. "Effects of Therapeutic Immunosuppressants on UVB Induced Inflammation and Skin Carcinogenesis in a Murine Model." The Ohio State University, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=osu1227116356.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Staatz, Christine Elizabeth. "Population pharmacokinetics of tacrolimus with pharmacodynamic exploration in different organ transplant groups /." St. Lucia, Qld, 2001. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe16521.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Dansirikul, Chantaratsamon. "Pharmacokinetic studies with sirolimus and tacrolimus /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18266.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

"Growing Human Organs in Animals: Interspecies Blastocyst Complementation as a Potential Solution for Organ Transplant Limitations." Master's thesis, 2020. http://hdl.handle.net/2286/R.I.62836.

Full text

Abstract:

abstract: Prior to the first successful allogeneic organ transplantation in 1954, virtually every attempt at transplanting organs in humans had resulted in death, and understanding the role of the immune mechanisms that induced graft rejection served as one of the biggest obstacles impeding its success. While the eventual achievement of organ transplantation is touted as one of the most important success stories in modern medicine, there still remains a physiological need for immunosuppression in order to make organ transplantation work. One such solution in the field of experimental regenerative medicine is interspecies blastocyst complementation, a means of growing patient-specific human organs within animals. To address the progression of immune-related constraints on organ transplantation, the first part of this thesis contains a historical analysis tracing early transplant motivations and the events that led to the discoveries broadly related to tolerance, rejection, and compatibility. Despite the advancement of those concepts over time, this early history shows that immunosuppression was one of the earliest limiting barriers to successful organ transplantation, and remains one of the most significant technical challenges. Then, the second part of this thesis determines the extent at which interspecies blastocyst complementation could satisfy modern technical limitations of organ transplantation. Demonstrated in 2010, this process involves using human progenitor cells derived from induced pluripotent stem cells (iPSCs) to manipulate an animal blastocyst genetically modified to lack one or more functional genes responsible for the development of the intended organ. Instead of directly modulating the immune response, the use of iPSCs with interspecies blastocyst complementation could theoretically eliminate the need for immunosuppression entirely based on the establishment of tolerance and elimination of rejection, while also satisfying the logistical demands imposed by the national organ shortage. Although the technology will require some further refinement, it remains a promising solution to eliminate the requirement of immunosuppression after an organ transplant.
Dissertation/Thesis
Masters Thesis Biology 2020

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Organ transplantation; Immunosuppression"

1

Gruber, Scott A. Local immunosuppression of organ transplants. New York: Chapman & Hall, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

FK506 and organ transplantation. Austin: R.G. Landes, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Oremus, Mark. Utility of monitoring mycophenolic acid in solid organ transplant patients. Rockville, MD: Agency for Healthcare Research and Quality, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Taylor, Charles B. Immunosuppression: New research. New York: Nova Biomedical Books, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Otley, Clark C. Skin disease in organ transplantation. New York: Cambridge University Press, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Current trends in transplantation: Drug therapy and monitoring. Abbott Park: Abbott Laboratories, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Transplantation dermatology. Basel: Karger, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

United States. Congress. Senate. Committee on Labor and Human Resources. Immunosuppressive Drug Therapy Act of 1986: Report together with additional views (to accompany S. 2536). [Washington, D.C.?: U.S. G.P.O., 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Pirsch, John. Transplantation drug manual. 5th ed. Austin, Tex: Landes Bioscience, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lum, Caliann T. Research advances in human transplantation. [Bethesda, Md.?]: General Clinical Research Centers Program, National Center for Research Resources, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Organ transplantation; Immunosuppression"

1

Geissler, Edward K. "Immunosuppression." In Skin Cancer after Organ Transplantation, 23–43. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-78574-5_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

McDermott, Jennifer K. "Complications of Immunosuppression." In Organ and Tissue Transplantation, 1–18. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-33280-2_21-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bianco, Christopher M., and Monique R. Robinson. "Chronic Immunosuppression Medications." In Organ and Tissue Transplantation, 1–33. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-33280-2_23-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Horn, Edward, and Moses Demehin. "Advances in Immunosuppression." In Organ and Tissue Transplantation, 1–16. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-33280-2_39-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

McDermott, Jennifer K. "Complications of Immunosuppression." In Organ and Tissue Transplantation, 205–22. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-58054-8_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bianco, Christopher M., and Monique R. Robinson. "Chronic Immunosuppression Medications." In Organ and Tissue Transplantation, 251–83. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-58054-8_23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Horn, Edward, and Moses Demehin. "Advances in Immunosuppression." In Organ and Tissue Transplantation, 467–82. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-58054-8_39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Blatter, Joshua A., and Peter H. Michelson. "Immunosuppression in Lung Transplantation." In Solid Organ Transplantation in Infants and Children, 1–13. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-08049-9_67-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Blatter, Joshua A., and Peter H. Michelson. "Immunosuppression in Lung Transplantation." In Solid Organ Transplantation in Infants and Children, 805–17. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-07284-5_67.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Djalilian, Ali R., and Edward J. Holland. "Local Immunosuppression in Corneal Transplantation." In Local Immunosuppression of Organ Transplants, 153–59. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-662-22105-1_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!